在荟萃分析中【 Andrew M 2022 】,已经证明接受TACE和TARE的患者的总生存期没有差异;然而,接受TARE治疗的患者发生HCC进展的时间(Time to HCC progression)明显更长。这些发现与唯一比较TACE和TARE的随机数据一致【 Salem R 2016 】。在一项个体荟萃(indiv...
Cho YY, Lee M, Kim HC, Chung JW, Kim YH, Gwak GY. Bae SH, Kim do Y, Heo J, Kim YJ1. Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis . PLoS One. 2016...